The information on this page is based on a number of underlying datasets, most of which are updated monthly. We maintain an update schedule which explains which version of each dataset we are currently relying on.
59 IRIS CRESCENT is a large flat of 64m², built sometime from 2012 onwards, which could now be worth an estimated £162,550. It was last sold for £109,250 in May 2012, which was around 52% above the average May 2012 flat price in the Lincoln local authority area. The most recent EPC inspection was July 2022, where the current energy rating was C, and the potential energy rating was C.
Land registry data shows one sale for 59 IRIS CRESCENT since 1st January 1995. The below table shows the price paid for the one sale, along with the average flat price in the Lincoln local authority area for the corresponding sale date. The average price is sourced from the Office for National Statistics' House Price Index (HPI).
| Date | Price | HPI Price | Variation from HPI |
|---|---|---|---|
2012 31 MAY | £109,250 | £72,046 | 52% above HPI |
59 IRIS CRESCENT might now be worth an estimated £162,550.
This is based on house price inflation of 48.8%, between May 2012 and May 2026, for flats, in the Lincoln local authority area, as calculated by the Office for National Statistics and published in their UK House Price Index (HPI).
The 48.8% inflationary increase is applied to the most recent sale price for 59 IRIS CRESCENT of £109,250 on 31st May 2012. For the value to have increased from £109,250 to £162,550 over the fourteen years to May 2026, the following assumptions must hold true:
59 IRIS CRESCENT is 64m² according to the EPC inspection conducted in July 2022. This puts it in the largest 40% of flats in Lincoln, based on EPC data. 65% of flats are smaller than 59 IRIS CRESCENT, and 32% of flats are larger. Note that EPC data is not available for all properties in Lincoln.
59 IRIS CRESCENT sits on a plot of roughly 0.019 of an acre, or 77m².
59 IRIS CRESCENT is located in LINCOLN, in the LN1 postcode district.
Most recent sales first: